NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

Romel Somwar et al. find that cancer-causing NTRK gene fusions resistant to one form of inhibitor therapy can be resistant to other inhibitor types. Using molecular simulations, they show that some NTRK1 mutations resistant to the type I inhibitor larotrectinib are hypersensitive to the type II inhi...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Romel Somwar, Nicolle E. Hofmann, Bryan Smith, Igor Odintsov, Morana Vojnic, Irina Linkov, Ashley Tam, Inna Khodos, Marissa S. Mattar, Elisa de Stanchina, Daniel Flynn, Marc Ladanyi, Alexander Drilon, Ujwal Shinde, Monika A. Davare
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Nature Portfolio 2020-12-01
Seri Bilgileri:	Communications Biology
Online Erişim:	https://doi.org/10.1038/s42003-020-01508-w
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors

Benzer Materyaller